In its quarterly qualitative update, Lonza reported a softer Q1, with performance across H1 expected to align with the full-year 2024 trajectory. Lonza confirms its 2024 outlook, projecting flat sales growth in constant exchange rates (CER) and a Core EBITDA…
The Bayer Group’s performance in the first quarter of the year met expectations, according to CEO Bill Anderson. “First-quarter sales declined slightly versus the prior year. The Pharmaceuticals Division saw gains in growth and profitability, and the Crop Science Division…
Bristol Myers Squibb (NYSE: BMY) has provided an update on its Phase 3 CheckMate -73L trial, revealing that it did not achieve its primary endpoint of progression-free survival (PFS) in patients with unresectable, locally advanced stage III non-small cell lung…
CRISPR Therapeutics (Nasdaq: CRSP), a company dedicated to pioneering gene-based medicines for severe illnesses, has unveiled its financial performance for the first quarter ending March 31, 2024. CEO and Chairman of CRISPR Therapeutics, Dr. Samarth Kulkarni, highlighted the notable progress…
GlycoMimetics, Inc. (Nasdaq: GLYC), a biotechnology company specializing in advanced therapies for cancer and inflammatory conditions, has released the top-line results from its Phase 3 global pivotal trial of uproleselan involving 388 patients with relapsed/refractory (R/R) acute myeloid leukemia (AML).…
Summary of Financial Highlights: In the first quarter of 2024, the company experienced significant growth across various metrics: Overall, the company demonstrated robust growth in revenues and product sales, despite challenges such as increased operating expenses and a shift in…
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, has announced its financial results for the first quarter ending March 31, 2024, along with notable recent business achievements. Yvonne Greenstreet, MBChB, Chief Executive Officer of Alnylam, commented, “The year…
Encouraging findings emerge from an interim analysis of the ECHO Phase III trial, indicating that AstraZeneca’s Calquence (acalabrutinib), when paired with standard-of-care chemoimmunotherapy—bendamustine and rituximab—achieved a significant improvement in progression-free survival (PFS) compared to standard treatment in previously untreated adults…
Novo Nordisk’s Q1 2024 Performance Highlights Growth and Expansion Novo Nordisk, a global healthcare company focusing on diabetes and other serious chronic diseases, has reported robust financial results for the first three months of 2024. Operating profit surged by 27%…
The DESTINY-Breast06 Phase III trial yielded encouraging results, demonstrating the effectiveness of Enhertu (trastuzumab deruxtecan) in improving progression-free survival (PFS) significantly and meaningfully compared to standard chemotherapy. This positive outcome was observed in patients with HR-positive, HER2-low metastatic breast cancer…
Merck (NYSE: MRK), also known as MSD outside of the United States and Canada, has revealed findings from its Phase 3 trial, STRIDE-10, assessing V116, the company’s advanced 21-valent pneumococcal conjugate vaccine designed for adults. The announcement took place at…
AbbVie (NYSE: ABBV) has released its financial results for the first quarter ending March 31, 2024. Richard A. Gonzalez, the chairman and CEO of AbbVie, expressed satisfaction with the company’s strong performance, highlighting their consistent operational execution. He also commended…
